Novartis Ag

Schering Aktiengesellschaft

Dana-farber-cancer Institute Inc.

The University of Texas System

Novartis Pharma Gmbh

Other

Sandoz Gmbh

Irm LLC

Novatis Ag

Gsf-international Research Institute for Environment and Health

Novartis Pharma Ag

Juergen Mestan

Doriano Fabbro

Markus Warmuth

Paul William Manley

Pascal Furet

Guido Bold

Werner Breitenstein

Joseph Schoepfer

Wen-Chung Shieh

Jeanette Marjorie Wood

Paul Allen Sutton

Raeann Wu

Stéphanie Monnier

Jürgen Mestan

Jörg Brozio

Giorgio Caravatti

Andreas Marzinzik

Bahaa Salem

Robert Martin Grotzfeld

Wolfgang Jahnke

Darryl Jones

Xavier Francois Andre Pelle

Andreas Huth

Dieter Seidelmann

Andrea Vaupel

Karl-Heinz Thierauch

Karl-Heinz Altmann

Andreas Menrad

Piotr Henryk Karpinski

Stefano Ferrari

Sandra Jacob

Martin Haberey

Bernhard Wietfeld

James Douglas Griffin

Carole Pissot Soldermann

Richard Heng

Martin Krüger

Andreas Floersheimer

Hans Michael Buerger

Francesco Hofmann

Janet Dawson King

Margaret A Cudd

Piotr “Peter” H Karpinski

Leila Alland

Vito Guagnano

Hans-Georg Capraro

Michael Hallek

Moshe Talpaz

Nicholas J Donato

Saliha Moussaoui

Ji Wu

Joerg Brozio

Nathanael Schiander Gray

Yi Liu

Eckhard Ottow

Marc Lang

Tetsuo Uno

Michael Mutz

Qiang Ding

Guobao Zhang

Bing Li

Stephanie Kay Dodd

Taebo Sim

Carlos Garcia-Echeverria

Carsten Spanka

Hans Michael Bürger

Michael Schirner

J&ouml;rg Frei

Jürg Zimmermann

Martin Kr&uuml;ger

Roderick A Porter

Juerg Zimmermann

Peter End

Gerhard Gross

Juerg Zimmerman

Joerg Frei

Uerg Zimmermann

Andreas Martin-Kohler

Urs Séquin

Jose Brüggen

Jörg Frei

J&uuml;rgen Mestan

Georg Martiny-Baron

Eugen Boss

Klaus Olaf Börnsen

Erich Alois Spieser

Ulrike Pfaar

Darryl Brynley Jones

Jorg Brozio

The present invention relates to compounds of formula (I): 

Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

The present invention relates to compounds of formula I: 

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The present invention relates to compounds of formula I: in which Y, Y, Y, Y, Y, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Crystalline forms of 4-methyl-N-3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of systemic mastocytosis.

Pyrimidylaminobenzamide derivatives for systemic mastocytosis

The invention provides a pharmaceutical combination comprising:

Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF.

Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis

Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

The invention relates to compounds of formula (I) wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Compounds and compositions as protein kinase inhibitors

The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(&#x2212;) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.

Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity

Growing community of inventors

Arlesheim, Switzerland

Paul William Manley